AAPL341.32+1.24 (+0.36%) ▲|ABBV266.20+3.00 (+1.14%) ▲|ABT109.56+2.29 (+2.13%) ▲|ACN171.48+6.82 (+4.14%) ▲|ADBE258.88+9.70 (+3.89%) ▲|AMAT451.28-25.18 (-5.28%) ▼|AMD432.93-21.69 (-4.77%) ▼|AMGN395.09+1.99 (+0.51%) ▲|AMT175.97+4.47 (+2.61%) ▲|AMZN227.71-3.15 (-1.36%) ▼|AVGO375.10-5.82 (-1.53%) ▼|AXP333.82-2.81 (-0.83%) ▼|BA212.31-9.26 (-4.18%) ▼|BAC61.89-0.74 (-1.17%) ▼|BKNG200.00+0.69 (+0.35%) ▲|BLK1,101.76+4.21 (+0.38%) ▲|BMY63.65+0.05 (+0.08%) ▲|BNY154.89-1.60 (-1.02%) ▼|BRK-B510.00-2.37 (-0.46%) ▼|C128.77-3.70 (-2.79%) ▼|CAT803.28-37.57 (-4.47%) ▼|CL92.19-0.54 (-0.58%) ▼|CMCSA24.44+0.25 (+1.03%) ▲|COF211.67-0.74 (-0.35%) ▼|COP118.37+4.27 (+3.74%) ▲|COST973.24+6.66 (+0.69%) ▲|CRM183.83+2.33 (+1.28%) ▲|CSCO116.35+0.77 (+0.66%) ▲|CVS108.31-1.03 (-0.94%) ▼|CVX192.55+4.97 (+2.65%) ▲|DE620.23-19.62 (-3.07%) ▼|DHR201.84+2.79 (+1.40%) ▲|DIS98.92+0.03 (+0.03%) ▲|DUK130.08+0.84 (+0.65%) ▲|EMR148.48-3.33 (-2.19%) ▼|FDX310.13-2.51 (-0.80%) ▼|GD393.38+0.19 (+0.05%) ▲|GE356.32-7.28 (-2.00%) ▼|GEV923.17-20.21 (-2.14%) ▼|GILD133.38-0.94 (-0.70%) ▼|GM91.00+0.70 (+0.77%) ▲|GOOG331.19-1.41 (-0.42%) ▼|GOOGL332.34-1.37 (-0.41%) ▼|GS990.92-42.42 (-4.11%) ▼|HD338.33-6.14 (-1.78%) ▼|HON242.76-4.30 (-1.74%) ▼|IBM227.34-0.22 (-0.09%) ▼|INTC83.85-2.45 (-2.84%) ▼|INTU326.39+13.40 (+4.28%) ▲|ISRG356.63-5.17 (-1.43%) ▼|JNJ268.16+1.43 (+0.54%) ▲|JPM350.20-7.12 (-1.99%) ▼|KO90.72+2.45 (+2.78%) ▲|LIN509.84-1.34 (-0.26%) ▼|LLY1,223.45+2.79 (+0.23%) ▲|LMT578.65-2.66 (-0.46%) ▼|LOW216.07-2.18 (-1.00%) ▼|LRCX258.03-11.58 (-4.30%) ▼|MA564.48+1.73 (+0.31%) ▲|MCD271.71-1.31 (-0.48%) ▼|MDLZ65.59+3.11 (+4.98%) ▲|MDT87.80+0.92 (+1.06%) ▲|META586.87-6.54 (-1.10%) ▼|MMM181.61-0.88 (-0.48%) ▼|MO75.43+0.61 (+0.82%) ▲|MRK130.75-1.07 (-0.81%) ▼|MS205.87-5.71 (-2.70%) ▼|MSFT392.47-0.89 (-0.23%) ▼|MU788.34-32.19 (-3.92%) ▼|NEE89.79+0.51 (+0.57%) ▲|NFLX72.02-0.38 (-0.52%) ▼|NKE42.55-0.50 (-1.16%) ▼|NOW113.16+2.54 (+2.30%) ▲|NVDA191.44-5.57 (-2.83%) ▼|ORCL117.86-2.10 (-1.75%) ▼|PEP145.02+2.16 (+1.51%) ▲|PFE25.22-0.03 (-0.12%) ▼|PG145.28-3.61 (-2.42%) ▼|PLTR123.59+0.06 (+0.05%) ▲|PM201.15+0.98 (+0.49%) ▲|QCOM159.03-3.85 (-2.36%) ▼|RTX217.66-0.92 (-0.42%) ▼|SBUX103.59+0.49 (+0.48%) ▲|SCHW105.77-0.20 (-0.19%) ▼|SO97.13+0.35 (+0.36%) ▲|SPG237.22+0.52 (+0.22%) ▲|T24.51-0.15 (-0.61%) ▼|TMO583.43+7.02 (+1.22%) ▲|TMUS181.76-0.63 (-0.35%) ▼|TSLA303.21-4.23 (-1.38%) ▼|TXN271.38-5.69 (-2.05%) ▼|UBER69.78-0.96 (-1.36%) ▼|UNH425.23-3.56 (-0.83%) ▼|UNP292.38-2.07 (-0.70%) ▼|UPS104.47-1.06 (-1.00%) ▼|USB63.56-0.88 (-1.36%) ▼|V369.53+2.94 (+0.80%) ▲|VZ48.16-0.04 (-0.07%) ▼|WFC85.13-1.74 (-2.00%) ▼|WMT113.21+0.11 (+0.10%) ▲|XOM158.57+5.53 (+3.61%) ▲|AAPL341.32+1.24 (+0.36%) ▲|ABBV266.20+3.00 (+1.14%) ▲|ABT109.56+2.29 (+2.13%) ▲|ACN171.48+6.82 (+4.14%) ▲|ADBE258.88+9.70 (+3.89%) ▲|AMAT451.28-25.18 (-5.28%) ▼|AMD432.93-21.69 (-4.77%) ▼|AMGN395.09+1.99 (+0.51%) ▲|AMT175.97+4.47 (+2.61%) ▲|AMZN227.71-3.15 (-1.36%) ▼|AVGO375.10-5.82 (-1.53%) ▼|AXP333.82-2.81 (-0.83%) ▼|BA212.31-9.26 (-4.18%) ▼|BAC61.89-0.74 (-1.17%) ▼|BKNG200.00+0.69 (+0.35%) ▲|BLK1,101.76+4.21 (+0.38%) ▲|BMY63.65+0.05 (+0.08%) ▲|BNY154.89-1.60 (-1.02%) ▼|BRK-B510.00-2.37 (-0.46%) ▼|C128.77-3.70 (-2.79%) ▼|CAT803.28-37.57 (-4.47%) ▼|CL92.19-0.54 (-0.58%) ▼|CMCSA24.44+0.25 (+1.03%) ▲|COF211.67-0.74 (-0.35%) ▼|COP118.37+4.27 (+3.74%) ▲|COST973.24+6.66 (+0.69%) ▲|CRM183.83+2.33 (+1.28%) ▲|CSCO116.35+0.77 (+0.66%) ▲|CVS108.31-1.03 (-0.94%) ▼|CVX192.55+4.97 (+2.65%) ▲|DE620.23-19.62 (-3.07%) ▼|DHR201.84+2.79 (+1.40%) ▲|DIS98.92+0.03 (+0.03%) ▲|DUK130.08+0.84 (+0.65%) ▲|EMR148.48-3.33 (-2.19%) ▼|FDX310.13-2.51 (-0.80%) ▼|GD393.38+0.19 (+0.05%) ▲|GE356.32-7.28 (-2.00%) ▼|GEV923.17-20.21 (-2.14%) ▼|GILD133.38-0.94 (-0.70%) ▼|GM91.00+0.70 (+0.77%) ▲|GOOG331.19-1.41 (-0.42%) ▼|GOOGL332.34-1.37 (-0.41%) ▼|GS990.92-42.42 (-4.11%) ▼|HD338.33-6.14 (-1.78%) ▼|HON242.76-4.30 (-1.74%) ▼|IBM227.34-0.22 (-0.09%) ▼|INTC83.85-2.45 (-2.84%) ▼|INTU326.39+13.40 (+4.28%) ▲|ISRG356.63-5.17 (-1.43%) ▼|JNJ268.16+1.43 (+0.54%) ▲|JPM350.20-7.12 (-1.99%) ▼|KO90.72+2.45 (+2.78%) ▲|LIN509.84-1.34 (-0.26%) ▼|LLY1,223.45+2.79 (+0.23%) ▲|LMT578.65-2.66 (-0.46%) ▼|LOW216.07-2.18 (-1.00%) ▼|LRCX258.03-11.58 (-4.30%) ▼|MA564.48+1.73 (+0.31%) ▲|MCD271.71-1.31 (-0.48%) ▼|MDLZ65.59+3.11 (+4.98%) ▲|MDT87.80+0.92 (+1.06%) ▲|META586.87-6.54 (-1.10%) ▼|MMM181.61-0.88 (-0.48%) ▼|MO75.43+0.61 (+0.82%) ▲|MRK130.75-1.07 (-0.81%) ▼|MS205.87-5.71 (-2.70%) ▼|MSFT392.47-0.89 (-0.23%) ▼|MU788.34-32.19 (-3.92%) ▼|NEE89.79+0.51 (+0.57%) ▲|NFLX72.02-0.38 (-0.52%) ▼|NKE42.55-0.50 (-1.16%) ▼|NOW113.16+2.54 (+2.30%) ▲|NVDA191.44-5.57 (-2.83%) ▼|ORCL117.86-2.10 (-1.75%) ▼|PEP145.02+2.16 (+1.51%) ▲|PFE25.22-0.03 (-0.12%) ▼|PG145.28-3.61 (-2.42%) ▼|PLTR123.59+0.06 (+0.05%) ▲|PM201.15+0.98 (+0.49%) ▲|QCOM159.03-3.85 (-2.36%) ▼|RTX217.66-0.92 (-0.42%) ▼|SBUX103.59+0.49 (+0.48%) ▲|SCHW105.77-0.20 (-0.19%) ▼|SO97.13+0.35 (+0.36%) ▲|SPG237.22+0.52 (+0.22%) ▲|T24.51-0.15 (-0.61%) ▼|TMO583.43+7.02 (+1.22%) ▲|TMUS181.76-0.63 (-0.35%) ▼|TSLA303.21-4.23 (-1.38%) ▼|TXN271.38-5.69 (-2.05%) ▼|UBER69.78-0.96 (-1.36%) ▼|UNH425.23-3.56 (-0.83%) ▼|UNP292.38-2.07 (-0.70%) ▼|UPS104.47-1.06 (-1.00%) ▼|USB63.56-0.88 (-1.36%) ▼|V369.53+2.94 (+0.80%) ▲|VZ48.16-0.04 (-0.07%) ▼|WFC85.13-1.74 (-2.00%) ▼|WMT113.21+0.11 (+0.10%) ▲|XOM158.57+5.53 (+3.61%) ▲|
21.2 C
New York
Wednesday, July 29, 2026

Tag: trials

newssourceFORcompanyinformationcontent1releasesmarket

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 23, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 23, 2026 /CNW/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

HD Korea Shipbuilding & Offshore Engineering Pursues AI-Driven Transformation of Shipbuilding Industry

HD Korea Shipbuilding & Offshore Engineering signs definitive agreement with Siemens to implement next-generation marine platform and establish a 3D single-data platformAims to build...

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery...

ALS Network Applauds House Passage of ACT for ALS Reauthorization Act

House approval marks a major milestone; ALS Network urges the Senate to act before September expirationLOS ANGELES, July 22, 2026 /PRNewswire/ -- The ALS...

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026.

Prenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)

Prenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated Information
Châtillon, France, July 6, 2026

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of...

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of...

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrials

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers